Upturn unsubscribed user
$1.14/ day, billed weekly
Cancel anytime
(Ad-Free, Unlimited access)​
NO CREDIT CARD REQUIRED
RVMD logo RVMD
Upturn stock ratingUpturn stock rating
RVMD logo

Revolution Medicines Inc (RVMD)

Upturn stock ratingUpturn stock rating
$38.5
Last Close (24-hour delay)
upturn advisory
PASS
  • BUY Advisory
  • SELL Advisory (Profit)​
  • SELL Advisory (Loss)​
  • Profit
  • Loss
  • Pass (Skip investing)
Upturn Stock infoUpturn Stock info Stock price based on last close
*as per simulation
(see disclosures)
Time period over
  • ALL
  • YEAR
  • MONTH
  • WEEK

Upturn Advisory Summary

07/10/2025: RVMD (4-star) is currently NOT-A-BUY. Pass it for now.

Upturn Star Rating

rating

Above Average Performance

These Stocks/ETFs, based on Upturn Advisory, frequently surpass the market, reflecting reliable and trustworthy advice.

Number of Analysts

rating

12 Analysts rated it

Moderately tracked stock, growing coverage, gaining market and investor attention.

1 Year Target Price $72.91

1 Year Target Price $72.91

Analysts Price Target For last 52 week
$72.91 Target price
52w Low $29.17
Current$38.5
52w High $62.4

Analysis of Past Performance

Type Stock
Historic Profit 91.32%
Avg. Invested days 89
Today’s Advisory PASS
Upturn Star Rating Upturn stock ratingUpturn stock rating
Upturn Advisory Performance Upturn Advisory Performance 4.0
Stock Returns Performance Upturn Returns Performance 4.0
Upturn Profits based on simulationUpturn Profits based on simulation Profits based on simulation
Upturn Profits based on simulationUpturn Profits based on simulation Last Close 07/10/2025

Key Highlights

Company Size Mid-Cap Stock
Market Capitalization 7.17B USD
Price to earnings Ratio -
1Y Target Price 72.91
Price to earnings Ratio -
1Y Target Price 72.91
Volume (30-day avg) 12
Beta 1.1
52 Weeks Range 29.17 - 62.40
Updated Date 07/11/2025
52 Weeks Range 29.17 - 62.40
Updated Date 07/11/2025
Dividends yield (FY) -
Basic EPS (TTM) -4.01

Analyzing Revenue: Products, Geography and Growth

Revenue by Products

Product revenue - Year on Year

Earnings Date

Report Date -
When -
Estimate -
Actual -

Profitability

Profit Margin -
Operating Margin (TTM) -

Management Effectiveness

Return on Assets (TTM) -23.09%
Return on Equity (TTM) -36.68%

Valuation

Trailing PE -
Forward PE -
Enterprise Value 5206692794
Price to Sales(TTM) 9035.1
Enterprise Value 5206692794
Price to Sales(TTM) 9035.1
Enterprise Value to Revenue 8370.02
Enterprise Value to EBITDA -9.71
Shares Outstanding 186268000
Shares Floating 168192142
Shares Outstanding 186268000
Shares Floating 168192142
Percent Insiders 1.99
Percent Institutions 105.97

ai summary icon Upturn AI SWOT

Revolution Medicines Inc

stock logo

Company Overview

overview logo History and Background

Revolution Medicines, Inc. is a clinical-stage precision oncology company focused on developing novel targeted therapies to inhibit frontier targets that drive intrinsic drug resistance and cancer growth. Founded in 2014, the company has built a robust pipeline of RAS(ON) inhibitors. Revolution Medicines went public in February 2020.

business area logo Core Business Areas

  • RAS(ON) Inhibitors: Focuses on developing inhibitors of RAS proteins in their active (GTP-bound) state, a novel approach to targeting cancers driven by RAS mutations.

leadership logo Leadership and Structure

Mark A. Goldsmith, M.D., Ph.D. (CEO). The company has a board of directors and is structured with research, development, clinical, and administrative departments.

Top Products and Market Share

overview logo Key Offerings

  • RMC-6236 (RAS(ON) Inhibitor): RMC-6236 is an oral RAS(ON) inhibitor targeting multiple KRAS variants. Currently in clinical trials. Competitors include Mirati Therapeutics (MRTX), Amgen (AMGN), and other companies developing RAS inhibitors.
  • RMC-9805 (KRAS G12C(ON) Inhibitor): RMC-9805 is a potent and selective KRAS G12C(ON) inhibitor designed to only interact with the protein when bound to GTP. Currently in clinical trials. Potential competitors: Mirati Therapeutics (MRTX), Amgen (AMGN).

Market Dynamics

industry overview logo Industry Overview

The oncology drug market is a large and rapidly growing market, driven by increasing cancer incidence, advances in cancer biology, and the development of new targeted therapies. The market is highly competitive, with numerous pharmaceutical and biotechnology companies developing and marketing cancer drugs.

Positioning

Revolution Medicines is positioned as a leader in the development of RAS(ON) inhibitors, a novel approach to targeting RAS-driven cancers. Their competitive advantage lies in their unique technology platform and expertise in RAS biology.

Total Addressable Market (TAM)

The TAM for RAS-targeted therapies is estimated to be in the billions of dollars. Revolution Medicines is positioned to capture a significant share of this market with its pipeline of RAS(ON) inhibitors.

Upturn SWOT Analysis

Strengths

  • Novel RAS(ON) inhibitor technology platform
  • Strong scientific expertise in RAS biology
  • Robust pipeline of RAS(ON) inhibitors
  • Experienced management team
  • Strong financial position

Weaknesses

  • Clinical-stage company with no currently marketed products
  • High development risk associated with novel therapies
  • Reliance on successful clinical trial outcomes
  • Competition from established pharmaceutical companies

Opportunities

  • Expansion of RAS(ON) inhibitor pipeline
  • Partnerships with pharmaceutical companies
  • Successful clinical trial results
  • Regulatory approvals
  • Expansion into new cancer indications

Threats

  • Clinical trial failures
  • Regulatory setbacks
  • Competition from other RAS inhibitors
  • Patent challenges
  • Economic downturn

Competitors and Market Share

competitor logo Key Competitors

  • MRTX
  • AMGN
  • DGX

Competitive Landscape

Revolution Medicines has an advantage in the RAS(ON) inhibitor space. The disadvantage includes being a small company versus AMGN. MRTX is more advanced with KRAS G12C inhibitors.

Growth Trajectory and Initiatives

Historical Growth: Revolution Medicines' growth is tied to its clinical program advancements and financial investments.

Future Projections: Future projections depend on the successful advancement of its pipeline and can be obtained from analyst reports.

Recent Initiatives: Revolution Medicines has recently focused on advancing its clinical programs for RMC-6236 and RMC-9805.

Summary

Revolution Medicines is a clinical-stage company with a novel technology platform targeting RAS-driven cancers. Its pipeline of RAS(ON) inhibitors shows promise. Its main challenge is clinical development and competition. The company has a strong scientific team but faces execution risks.

Peer Comparison

Sources and Disclaimers

Data Sources:

  • Revolution Medicines Investor Relations, SEC Filings, Analyst Reports

Disclaimers:

This analysis is for informational purposes only and should not be considered investment advice. Market data and financial figures are subject to change.

Upturn AI SummarizationUpturn AI Summarization AI Summarization is directionally correct and might not be accurate.

Upturn AI SummarizationUpturn AI Summarization Summarized information shown could be a few years old and not current.

Upturn AI SummarizationUpturn AI Summarization Fundamental Rating based on AI could be based on old data.

Upturn AI SummarizationUpturn AI Summarization AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.

About Revolution Medicines Inc

Exchange NASDAQ
Headquaters Redwood City, CA, United States
IPO Launch date 2020-02-13
CEO, President & Chairman Dr. Mark A. Goldsmith Ph.D.
Sector Healthcare
Industry Biotechnology
Full time employees 616
Full time employees 616

Revolution Medicines, Inc., a clinical-stage precision oncology company, develops novel targeted therapies for RAS-addicted cancers. The company's research and development pipeline consist of RAS(ON) inhibitors that binds RAS variants to be used as monotherapy in combination with other RAS(ON) inhibitors and/or in combination with RAS companion inhibitors or other therapeutic agents, and RAS companion inhibitors to suppress cooperating targets and pathways that sustain RAS-addicted cancers. Its RAS(ON) inhibitors include daraxonrasib (RMC-6236), elironrasib G12C (RMC-6291), and zoldonrasib G12D (RMC-9805), which are in phase 1 clinical trial; and development candidates comprise RMC-5127 (G12V), RMC-0708 (Q61H), and RMC-8839 (G13C). The company's RAS companion inhibitors include RMC-4630 that is in phase 2 clinical trial; RMC-5552, a selective inhibitor of mTORC1 signaling in tumors, which is in phase 1 clinical trial; and RMC-5845 that targets SOS1. Revolution Medicines, Inc. was incorporated in 2014 and is headquartered in Redwood City, California.